CIM Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $349K | Sell |
452
-2
| -0.4% | -$1.53K | 0.09% | 178 |
|
|
2025
Q4 | $350K | Hold |
454
| – | – | 0.09% | 169 |
|
|
2025
Q3 | $255K | Sell |
454
-466
| -51% | -$263K | 0.07% | 195 |
|
|
2025
Q2 | $569K | Buy |
920
+459
| +100% | +$256K | 0.11% | 167 |
|
|
2025
Q1 | $292K | Hold |
461
| – | – | 0.07% | 182 |
|
|
2024
Q4 | $328K | Buy |
461
+2
| +0.4% | +$1.68K | 0.1% | 179 |
|
|
2024
Q3 | $483K | Sell |
459
-9
| -2% | -$10K | 0.14% | 125 |
|
|
2024
Q2 | $492K | Sell |
468
-3
| -0.6% | -$2.91K | 0.15% | 127 |
|
|
2024
Q1 | $453K | Hold |
471
| – | – | 0.14% | 153 |
|
|
2023
Q4 | $414K | Sell |
471
-200
| -30% | -$165K | 0.13% | 153 |
|
|
2023
Q3 | $552K | Sell |
671
-11
| -2% | -$8.64K | 0.2% | 106 |
|
|
2023
Q2 | $490K | Buy |
682
+2
| +0.3% | +$1.54K | 0.17% | 122 |
|
|
2023
Q1 | $559K | Buy |
680
+112
| +20% | +$84.5K | 0.21% | 108 |
|
|
2022
Q4 | $410K | Sell |
568
-10
| -2% | -$7.38K | 0.16% | 132 |
|
|
2022
Q3 | $398K | Buy |
578
+24
| +4% | +$15.1K | 0.18% | 119 |
|
|
2022
Q2 | $327K | Sell |
554
-3
| -0.5% | -$1.95K | 0.14% | 153 |
|
|
2022
Q1 | $389K | Sell |
557
-505
| -48% | -$319K | 0.13% | 149 |
|
|
2021
Q4 | $671K | Sell |
1,062
-19
| -2% | -$11.7K | 0.2% | 103 |
|
|
2021
Q3 | $654K | Sell |
1,081
-6
| -0.6% | -$3.73K | 0.21% | 102 |
|
|
2021
Q2 | $607K | Sell |
1,087
-18
| -2% | -$9.12K | 0.19% | 114 |
|
|
2021
Q1 | $523K | Sell |
1,105
-40
| -3% | -$19.5K | 0.16% | 127 |
|
|
2020
Q4 | $553K | Buy |
+1,145
| New | +$618K | 0.18% | 108 |
|
|
2020
Q1 | – | Sell |
-996
| Closed | -$374K | – | 228 |
|
|
2019
Q4 | $374K | Hold |
996
| – | – | 0.15% | 141 |
|
|
2019
Q3 | $276K | Sell |
996
-105
| -10% | -$31.1K | 0.1% | 251 |
|
|
2019
Q2 | $345K | Buy |
1,101
+42
| +4% | +$14K | 0.13% | 199 |
|
|
2019
Q1 | $435K | Hold |
1,059
| – | – | 0.17% | 161 |
|
|
2018
Q4 | $396K | Sell |
1,059
-44
| -4% | -$16.1K | 0.17% | 150 |
|
|
2018
Q3 | $446K | Hold |
1,103
| – | – | 0.16% | 174 |
|
|
2018
Q2 | $381K | Sell |
1,103
-32
| -3% | -$10K | 0.13% | 224 |
|
|
2018
Q1 | $391K | Sell |
1,135
-28
| -2% | -$9.74K | 0.13% | 214 |
|
|
2017
Q4 | $437K | Sell |
1,163
-18
| -2% | -$7.29K | 0.15% | 195 |
|
|
2017
Q3 | $528K | Sell |
1,181
-67
| -5% | -$31.9K | 0.19% | 151 |
|
|
2017
Q2 | $613K | Sell |
1,248
-1,276
| -51% | -$558K | 0.22% | 119 |
|
|
2017
Q1 | $978K | Buy |
+2,524
| New | +$936K | 0.34% | 59 |
|
|
2015
Q2 | – | Sell |
-1,935
| Closed | -$874K | – | 275 |
|
|
2015
Q1 | $874K | Buy |
+1,935
| New | +$820K | 0.38% | 97 |
|
|
2014
Q3 | – | Sell |
-4,412
| Closed | -$1.25M | – | 212 |
|
|
2014
Q2 | $1.25M | Sell |
4,412
-124
| -3% | -$36.8K | 0.63% | 56 |
|
|
2014
Q1 | $1.36M | Sell |
4,536
-105
| -2% | -$32.3K | 0.63% | 40 |
|
|
2013
Q4 | $1.28M | Buy |
4,641
+330
| +8% | +$94.9K | 0.65% | 51 |
|
|
2013
Q3 | $1.35M | Buy |
+4,311
| New | +$1.13M | 0.8% | 37 |
|
Other funds holding REGN
VCM
N
CIM Investment Management's REGN Position: Q1 2026 in Review
CIM Investment Management reduced its Regeneron Pharmaceuticals (REGN) stake by 0.44% in Q1 2026, selling an estimated $1.53K and leaving 452 shares worth $349K. The position accounts for 0.09% of the portfolio, ranked #178.
CIM Investment Management first reported a position in REGN in Q3 2013 and has held it in 39 quarters since. The position peaked at $1.36M in Q1 2014. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- CIM Investment Management held 452 shares of Regeneron Pharmaceuticals worth $349K as of Q1 2026.
- CIM Investment Management sold 2 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.53K.
- Regeneron Pharmaceuticals made up 0.09% of CIM Investment Management's portfolio in Q1 2026, its #178 holding.
- CIM Investment Management first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 39 quarters since.
- CIM Investment Management's Regeneron Pharmaceuticals position peaked at $1.36M in Q1 2014.
- 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on CIM Investment Management's 13F filing for Q1 2026, filed 19 May 2026.